Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Contract Award for the supply of DPYD testing kits to NHS Wales
Estimated to be worth £232,000 across two years
Manchester, UK – June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has been awarded the contract to supply its Elucigene DPYD testing kits to NHS Wales. The contract award is for two years (for a period of 12 months with the option to extend for a further 12 months) and is estimated to be worth £232,000.
The Elucigene DPYD1 screens cancer patients prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects. Wales was the first nation in the UK to routinely implement this screening and offer the DPYD test to all patients, with Yourgene being the sole provider, as announced in October 2020.
Due to the considerable increase in the demand for the test the All Wales Genomics Laboratory (AWMGL) has awarded Yourgene this contract, due to commence in July 2021. As it has already been validated, AWMGL deems the Company’s oncology product the only technology suitable for meeting the lab requirement, allowing the Company to eliminate an extensive tender process.
Lyn Rees, CEO of Yourgene Health plc, commented: “We are extremely pleased to be awarded this tender to supply our IVD-marked oncology product to NHS Wales, with our differentiated technology deemed the only technology suitable for meeting the lab requirements to deliver the service. We are proud to see this form of personalised medicine increasing in demand and routinely being used across Wales.”
1 Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU). 5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 |
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 |
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison | Tel: +44 (0)20 7710 7600 |
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07980 541 893 Mob: 07584 391 303 |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
